Outcome

Improvement

Relative Risk · 95% CI

27%0.73 · 0.73–0.73

Death/ICU

38%0.62 · 0.62–0.62

Mortality, >40yo

33%0.67 · 0.67–0.67

Mortality, >40yo w/comorbidities

44%0.56 · 0.56–0.56

no CI

00.511.52+

← Ivermectin
reduces riskIvermectin
increases risk →

Lower mortality with ivermectin

.hsva .va--anim-stagger :is(.va__row,.plot__row,.va__verdict){opacity:1}.hsva .va--anim .plot__shade{opacity:var(--shade-opacity)}.hsva .va--anim-stagger .ci{transform:translateY(-50%)}.hsva .va--anim-stagger .pt{transform:none}.hsva .va--anim-settle .pt{left:calc(min(var(--pt), 2) / 2 * 100%)}.hsva .va--anim-settle .ci{left:calc(var(--lo) / 2 * 100%);width:calc((var(--hi) - var(--lo)) / 2 * 100%)}

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.0000000001 from 106 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance. 

No treatment is 100% effective.
Protocols combine treatments.

c19early.org

Meta-analysis

News report on the use of ivermectin in La Pampa, Argentina, showing lower mortality with treatment.

This study is excluded in the after exclusion results of meta-analysis: minimal details provided.

Important missing comments or errors? Let us know.

OutcomeImprovementEffect · pTreatmentControl

risk of death 27.4% lower · RR 0.73 · 27.4% lowerRR 0.73 3,269 18,149 treatment 3,269, control 18,149

risk of death/ICU 38.0% lower · RR 0.62 · 38.0% lowerRR 0.62 3,269 18,149 treatment 3,269, control 18,149

risk of death 33.4% lower · RR 0.67 · 33.4% lowerRR 0.67 3,269 18,149 treatment 3,269, control 18,149>40yo

risk of death 44.0% lower · RR 0.56 · 44.0% lowerRR 0.56 3,269 18,149 treatment 3,269, control 18,149>40yo including comorbidities

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

La Pampa et al., 10 Aug 2021, retrospective, Argentina, preprint, 1 author, dosage 600μg/kg days 1-5.

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (106)61%

Mortality (54)47%

Ventilation (20)35%

ICU admission (15)40%

Hospitalization (31)34%

Recovery (41)38%

Cases (17)79%

Viral clearance (33)44%

RCTs (54)53%

Prophylaxis (18)84%

Early (39)62%

Late (49)40%

after exclusions

00.511.5+

← Ivermectin
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

La Pampa expondrá a la comunidad científica los resultados del Programa de Intervención Monitoreado de Ivermectina

Ivermectin for COVID-19